cardiovascular research unit
Activities
The Cardiovascular Research Unit aims to better understand the role of RNAs in heart and brain diseases. Our goal is to develop RNA-based biomarkers and therapeutic approaches to personalise health care. Our current focus is on heart failure, cardiac arrest and Parkinson’s disease.
MICRA is a very promising biomarker candidate due to its stability in the blood allowing a quantification in blood samples.
Yvan Devaux, PhD, Head of the Cardiovascular Research Unit (CVRU)
Projects & clinical trials
Our ongoing research projects address two major areas:
Biomarkers
Using high-throughput transcriptomics tools, the team seeks to develop RNA-based diagnostic and prognostic biomarkers for cardiovascular and brain diseases. Research projects focus on non-coding RNAs: microRNAs, long non-coding RNAs, and circular RNAs.
Therapeutics
By focusing on the mechanisms by which RNAs regulate the development of diseases, the group aims to facilitate drug discovery.
Strategic goals
- Address the main causes of mortality and morbidity in developed countries: heart and brain diseases
- Fulfil unmet medical needs: lack of diagnostic tools and drugs for personalised healthcare
- Develop networks of international collaborators
- Collaborate with private partners to bring research products to clinical application
- Perform translational research to push forward personalised medicine.
The group coordinates the EU-CardioRNA COST Action CA17129 network (www.cardiorna.eu) and the Cardiolinc™ network (www.cardiolinc.org), which are consortia of research groups aimed at advancing research on deciphering the role of RNAs in cardiovascular disease.
The group also coordinates the H2020 COVIRNA project which aims to develop RNA-based prognostic tools for COVID-19 patients (www.covirna.eu).
The group is partner of IMI2 CARDIATEAM project (www.cardiateam.eu ) and EU-Cardioprotection COST Action CA16225 (www.cardioprotection.eu).
Featured team members
-
Shubhra
Acharya M.S.
-
Yvan
Devaux Ph.D.
Group leader -
Andrew
Lumley Research Engineer -
Mélanie
Vausort M.S.
Research Engineer -
Adriana
Voicu
Scientific publications
-
Methodological considerations for circulating long noncoding RNA quantification – 01/01/2022
-
Regulation of N6-Methyladenosine after Myocardial Infarction – 22/07/2022
-
MicroRNAs as biomarkers in the brain-heart axis? – 11/07/2022
-
Noncoding RNAs in age-related cardiovascular diseases – 16/03/2022
-
Dissecting the transcriptome in cardiovascular disease – 23/03/2021
-
Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium – 10/03/2022
-
Editorial – 23/02/2022
-
Challenges of microRNA-based biomarkers in clinical application for cardiovascular diseases – 01/02/2022
-
Association between Dietary Factors and Constipation in Adults Living in Luxembourg and Taking Part in the ORISCAV-LUX 2 Survey – 28/12/2021
-
Leveraging non-coding RNAs to fight cardiovascular disease – 21/12/2021
-
Relevance of N6-methyladenosine regulators for transcriptome – 01/11/2021
-
Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside – 14/10/2021
-
Non-coding RNAs and stem cells – 01/10/2021
-
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria – 13/09/2021
-
The circadian clock remains intact, but with dampened hormonal output in heart failure – 01/09/2021
-
Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome – 07/07/2021
-
N6-Methyladenine in Eukaryotic DNA – 24/05/2021
-
Conclusions and perspectives – 06/03/2021
-
Epigenetics in Cardiovascular Disease – 06/03/2021
-
Long noncoding RNAs and circular RNAs as heart failure biomarkers – 06/03/2021
Related News
-
Hypertension: know what is behind your numbers
-
Can the “dark side” of the genome help fight cardiovascular disease?
-
EU-CardioRNA COST Action: LIH plays a leading role in international collaborative research on heart disease
-
Three LIH projects to be supported by “Marie Sklodowska-Curie Individual Fellowships”
